|
|
|
|
Cubist Pharmaceuticals Announces Full Year 2009 Total Net Revenues of $562.1 Million
GAAP DILUTED NET INCOME OF $0.38 PER SHARE IN FOURTH QUARTER GAAP DILUTED NET INCOME OF $1.36 PER SHARE FOR FULL YEAR NON-GAAP DILUTED NET INCOME OF $2.29 PER SHARE FOR FULL YEAR LEXINGTON, Mass.-- (BUSINESS WIRE) -- Cubist Pharmaceuticals, Inc.(NASDAQ: CBST...
|
|
|
Cubist Pharmaceuticals Announces Full Year 2009 Total Net Revenues of $562.1 Million
GAAP DILUTED NET INCOME OF $0.38 PER SHARE IN FOURTH QUARTER GAAP DILUTED NET INCOME OF $1.36 PER SHARE FOR FULL YEAR NON-GAAP DILUTED NET INCOME OF $2.29 PER SHARE FOR FULL YEAR LEXINGTON, Mass.--(EON: Enhanced Online News)--Cubist Pharmaceuticals, Inc....
|
|
|
Cubist Pharmaceuticals Announces Full Year 2009 Total Net Revenues of $562.1 Million
LEXINGTON, Mass.-- (NASDAQ: CBST) today announced results for the fourth quarter and year ended December 31, 2009. Cubist acquired Calixa Therapeutics Inc. in December Operating income grew 52% over 2008 Total net revenues for 2009 increased 30% over...
|
|
|
Cubist Pharmaceuticals Announces Full Year 2009 Total Net Revenues of $562.1 Million
GAAP DILUTED NET INCOME OF $0.38 PER SHARE IN FOURTH QUARTER GAAP DILUTED NET INCOME OF $1.36 PER SHARE FOR FULL YEAR NON-GAAP DILUTED NET INCOME OF $2.29 PER SHARE FOR FULL YEAR LEXINGTON, Mass.--(BUSINESS WIRE)-- (NASDAQ: CBST - News) today announced results...
|
|
|
Cubist Pharmaceuticals Announces Full Year 2009 Total Net Revenues of $562.1 Million
LEXINGTON, Mass.(Business Wire) -- Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced results for the fourth quarter and year ended December 31, 2009. Cubist acquired Calixa Therapeutics Inc. in December Operating income grew 52% over 2008...
|
|
|
Cubist Pharmaceuticals Announces Full Year 2009 Total Net Revenues of $562.1 Million
- (NASDAQ: CBST) today announced total revenues for both the fourth quarter and full year ended December 31, 2009.Fourth Quarter and Full Year Highlights: Full year 2009 U.S. CUBICIN (daptomycin for injection) net product revenues of $524.0 million Fourth...
|
|
|
Cubist Pharmaceuticals Releases 4Q and Full Year 2009 Results - Z...
Company: Cubist Pharmaceuticals, Inc.(CBST) Cubist Pharmaceuticals, Inc. has announced total revenues for both the fourth quarter and full year ended December 31. In a release on January 11, the Company noted that fourth quarter 2009 U.S. Cubicin net...
|
|
|
Cubist Pharmaceuticals reports total revenues for fourth-quarter and full-year 2009
Cubist Pharmaceuticals, Inc.(NASDAQ: CBST) today announced total revenues for both the fourth quarter and full year ended December 31, 2009. Fourth Quarter and Full Year Highlights: Full year 2009 U.S. CUBICIN (daptomycin for injection) net product...
|
|
|
Cubist Pharmaceuticals Announces Full Year 2009 Total Net Revenues of $562.1 Million
LEXINGTON, Mass.--(BUSINESS WIRE)-- (NASDAQ: CBST) today announced total revenues for both the fourth quarter and full year ended December 31, 2009.Fourth Quarter and Full Year Highlights: Fourth quarter 2009 U.S. CUBICIN net product revenues of $147.8...
|
|
|
Cubist Pharmaceuticals Announces Full Year 2009 Total Net Revenues of $562.1 Million
Companies mentioned in this article: Cubist Pharmaceuticals, Inc.LEXINGTON, Mass. -- (BUSINESS WIRE) -- Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced total revenues for both the fourth quarter and full year ended December 31, 2009. Fourth...
|
|
|
Cubist Pharmaceuticals Announces Full Year 2009 Total Net Revenues of $562.1 Million
LEXINGTON, Mass.(BUSINESS WIRE) Cubist Pharmaceuticals, Inc.(NASDAQ: CBST) today announced total revenues for both the fourth quarter and full year ended December 31, 2009. Fourth Quarter and Full Year Highlights: Fourth quarter 2009 U.S. CUBICIN net...
|
|
|
Cubist Pharma (CBST) Provides Q409 and FY09 Revenues
Cubist Pharmaceuticals, Inc.(NASDAQ: CBST) today announced total revenues for both the fourth quarter and full year ended December 31, 2009. Fourth Quarter and Full Year Highlights:Full year 2009 U.S. CUBICIN (daptomycin for injection) net product...
|
|
|
Cubist Pharmaceuticals Announces Full Year 2009 Total Net Revenues of $562.1 Million
LEXINGTON, Mass.--(BUSINESS WIRE)-- (NASDAQ: CBST) today announced total revenues for both the fourth quarter and full year ended December 31, 2009.Fourth Quarter and Full Year Highlights: Full year 2009 U.S. CUBICIN (daptomycin for injection) net product...
|
|
|
Cubist Pharmaceuticals Announces Full Year 2009 Total Net Revenues of $562.1 Million
LEXINGTON, Mass.Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced total revenues for both the fourth quarter and full year ended December 31, 2009. Fourth Quarter and Full Year Highlights: Full year 2009 U.S. CUBICIN (daptomycin for injection...
|
|
|
Cubist Pharmaceuticals Announces Full Year 2009 Total Net Revenues of $562.1 Million
GA_googleFillSlot("Press336"); GA_googleFillSlot("Press160"); LEXINGTON, Mass.- (Business Wire) (NASDAQ: CBST) today announced total revenues for both the fourth quarter and full year ended December 31, 2009. Fourth Quarter and Full Year Highlights: Full...
|
|
|
Cubist Pharmaceuticals Announces Full Year 2009 Total Net Revenues of $562.1 Million
LEXINGTON, Mass.- (BUSINESS WIRE) - (NASDAQ: CBST) today announced total revenues for both the fourth quarter and full year ended December 31, 2009. Fourth Quarter and Full Year Highlights: Fourth quarter 2009 U.S. CUBICIN net product revenues of $147.8...
|
|
|
Cubist Pharmaceuticals Announces Full Year 2009 Total Net Revenues of $562.1 Million
Cubist Pharmaceuticals, Inc.(NASDAQ: CBST) today announced total revenues for both the fourth quarter and full year ended December 31, 2009. Fourth Quarter and Full Year Highlights: Fourth quarter 2009 U.S. CUBICIN net product revenues of $147.8 million ...
|
|
|
Cubist Pharmaceuticals Announces Full Year 2009 Total Net Revenues of $562.1 Million
Cubist Pharmaceuticals, Inc.(NASDAQ: CBST) today announced total revenues for both the fourth quarter and full year ended December 31, 2009. Fourth Quarter and Full Year Highlights: Full year 2009 U.S. CUBICIN (daptomycin for injection) net product...
|
|
|
Cubist Pharmaceuticals and the New England Patriots Radio Network Recognize Innovative Science Teachers
Adams involves her students in designing lesson plans and labs, and she makes science come alive with innovative demonstrations that include having students simulate faults in the earths crust with modeling clay, using gummy worms to illustrate cell transport,...
|
|
|
Cubist Pharmaceuticals Completes Acquisition Of Calixa Therapeutics
2009-12-1616:07ET - News Release Company Website: http://www.cubist.com LEXINGTON, Mass.-- (Business Wire) Cubist Pharmaceuticals, Inc., (NASDAQ: CBST) a leading acute care therapeutics company has completed its previously announced acquisition of Calixa...
|
|
|
Cubist Pharmaceuticals Completes Acquisition Of Calixa Therapeutics
LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc., (NASDAQ: CBST - News) a leading acute care therapeutics company has completed its previously announced acquisition of Calixa Therapeutics Inc., a biopharmaceutical company focused on the...
|
|
|
Trial Date Set for Cubicin Patent Litigation
- Cubist Pharmaceuticals, Inc.(NASDAQ: CBST) today announced that a trial date has been set for patent litigation in the U.S. District Court for the District of Delaware against Teva Parenteral Medicines, Inc. (TPM), Teva Pharmaceuticals USA, Inc. and...
|
|
|
Cubist Pharmaceuticals Closes Enrollment Early in CONSERV-1 and CONSERV-2 Ph. 2 Trials for CB-500,929 (Ecall
Cubist then determined that the best path forward, with more than 450 patients now enrolled in CONSERV-1 and CONSERV-2 combined, was to end enrollment, complete follow up of patients who have been treated, and move forward quickly toward data lock and a...
|
